Online appendix (Figures)

Transcription

1 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl Online appendix (Figures) 5,, 4,5, 4,, of thyroid hormones of L-thyroxine 3,5, 3,, 15. of phenprocoumon of methiamazole 2,5, 2,, 1,5, 1 concerns with thyroid hormones concerns with L-thyroxine 1,, 5, 5. concerns with phenprocoumon concerns with methiamazole Figure a). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with a narrow therapeutic index or variable bioavailability between July 211 and. (eissn: ISSN: X) 1

2 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 14. 4, 35, 3, 25, 2, 15, 1, of estradiol TTS of fentanyl TTS of buprenorphine TTS concerns with estradiol TTS concerns with fentanyl TTS concerns with buprenorphine TTS 5, 2. Figure b). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with the dosage form transdermal therapeutic system (TTS) between July 211 and. (eissn: ISSN: X) 2

3 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Percentage of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 14. 4, 35, 3, 25, 2, 15, 1, 5, of methotrexate (parenteral use) of beclometasone (for inhalation) of lorazepam of ondansetron concerns with methotrexate (parenteral use) concerns with beclometasone (for inhalation) concerns with lorazepam concerns with ondansetron Figure c). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for methotrexate for parenteral use, beclomethasone for inhalation, lorazepam and ondansetron between July 211 and. (eissn: ISSN: X) 3

4 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 2, 1 18, 9. 16, 8. 14, 7. 12, 1, 8, 6, 4, of cefixime of cefpodoxime concerns with cefixime concerns with cefpodoxime 2, 1. Figure d). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with different package sizes between the prescribed (and dispensed) products (cephalosporin antibiotics) and the products listed in rebate contracts between July 211 and. (eissn: ISSN: X) 4

5 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Percentace pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 4, 1 of hydromorphone of morphine 35, 8. of olanzapine 3, 25, 2, 15, 1, 5, of levodopa + decarboxylase inhibit. concerns with hydromorphone concerns with morphine concerns with olanzapine concerns with levodopa + decarboxylase inhibit. Figure e). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs intended to treat severe disease states (e.g., schizophrenia, severe pain, Parkinson disease) between July 211 and. (eissn: ISSN: X) 5